Woodmansee, WhitneyGordon, Murray B.Molitch, Mark E.Ioachimescu, Adriana G.Carver, Don W.Mirakhur, BelooCox, DavidSalvatori, Roberto2018-07-252018Woodmansee, Whitney W., Murray B. Gordon, Mark E. Molitch, Adriana G. Ioachimescu, Don W. Carver, Beloo Mirakhur, David Cox, and Roberto Salvatori. 2018. “Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis.” Endocrine 61 (1): 105-117. doi:10.1007/s12020-018-1615-3. http://dx.doi.org/10.1007/s12020-018-1615-3.http://nrs.harvard.edu/urn-3:HUL.InstRepos:37298294Purpose This 2-year analysis assessed frequency of comorbidities and comorbidity screening in the Somatuline® (lanreotide, LAN) Depot for Acromegaly (SODA) registry. Methods: Patient data collected included pituitary hormone deficiencies, sleep studies, echocardiograms, gallbladder sonographies, colonoscopies, and glycated hemoglobin (HbA1c) levels. Insulin-like growth factor-1 (IGF-1) and growth hormone levels in patients with (DM) and without (non-DM) diabetes mellitus were analyzed. Results: There were 241 patients enrolled. Pituitary hormone deficiencies were reported more frequently at enrollment in male (56.9%) vs female patients (32.0%; p < 0.001). TSH deficiency was the most common endocrine deficiency (69.8%), followed by gonadotropin deficiency (62.3%). Screening tests reported at enrollment: sleep studies in 29.9% (79.2% had sleep apnea), echocardiogram in 46.1% (46.8% abnormal), gallbladder sonography in 18.7% (17.8% had gallstones), and colonoscopy in 48.1% (35.3% had polyps). Follow-up studies were reported less frequently at 1 and 2 years. HbA1c data were reported in 30.8% and 41.2% after 1 and 2 years. HbA1c levels were similar at 1 and 2 years of LAN therapy among DM and non-DM patients with available data. Fewer DM vs non-DM patients achieved IGF-1 below upper limit of normal at Month 24 (58.3% vs 80.6%; p = 0.033). Conclusions: Fewer than half of patients in SODA had screening results reported at enrollment for sleep apnea, cardiomyopathy, and colon polyps. Gallbladder imaging was reported in a minority of patients. Lower IGF-1 control rates were observed in DM vs non-DM patients at Month 24. These data suggest a need for better monitoring of comorbidities in US acromegaly patients.en-USAcromegalyComorbiditiesExtended-ReleaseLanreotide Depot/AutogelObservational StudyRegistryJournal Article2018-07-2510.1007/s12020-018-1615-3